GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (BOM:543635) » Definitions » Change In Other Working Capital

Piramal Pharma (BOM:543635) Change In Other Working Capital : ₹0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Change In Other Working Capital?

Piramal Pharma's Change In Other Working Capital for the quarter that ended in Sep. 2024 was ₹0 Mil. It means Piramal Pharma's Other Working Capital stayed the same from Jun. 2024 to Sep. 2024 .

Piramal Pharma's Change In Other Working Capital for the fiscal year that ended in Mar. 2024 was ₹6,888 Mil. It means Piramal Pharma's Other Working Capital increased by ₹6,888 Mil from Mar. 2023 to Mar. 2024 .

Piramal Pharma Change In Other Working Capital Historical Data

The historical data trend for Piramal Pharma's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Change In Other Working Capital Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Change In Other Working Capital
-369.00 685.20 -2,187.00 6,888.40

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Piramal Pharma Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (BOM:543635) » Definitions » Change In Other Working Capital
Comparable Companies
BOM:533573 BOM:524816 BOM:543064 BOM:506820 BOM:540596 BOM:500126 BOM:540222 BOM:532482 BOM:524742 BOM:543322 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
PPLPHARMA:India
Address
Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Website
https://www.piramal.com
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines